{"title":"Investigation of a Glioblastoma Risk-Associated SNP of the PTPRB Gene in Familial Glioblastoma","authors":"H. Nalkiran, Sema Yılmaz Rakıcı, Ihsan Nalkiran","doi":"10.37047/jos.2022-93852","DOIUrl":"https://doi.org/10.37047/jos.2022-93852","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69823922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Alkan, Bilge Can Uyar, Ece Dilan Bozkurt, Resmiye Irmak Yüzügüldü, E. Özgür, Sait Ki̇tapli, Özgür Tanrıverdi
ABS TRACT Lobular capillary hemangioma (LCH) or pyogenic granuloma is a rare benign lesion originating from the nasal cavity. We pre-sent a case of nasal LCH successfully palliated with sunitinib. A 65-year-old male patient was hospitalized because of swelling and hyper-emia in the periorbital region for 3 months. A month before admission, episodic epistaxis occurred. Magnetic resonance imaging showed a 35×62×63-mm solid mass filling the right half of the nasal cavity. The biopsy showed LCH, and the patient was diagnosed with metastatic renal cell carcinoma (RCC). The tumor board discussed a strategy that can primarily treat metastatic RCC and symptomatic palliation of LCH. Moreover, sunitinib treatment provided palliation of symptoms related to nasal LCH. He reported that swelling, pain, and epistaxis disappeared during the treatment.
{"title":"Management of Nasal Lobular Capillary Hemangioma with Sunitib","authors":"A. Alkan, Bilge Can Uyar, Ece Dilan Bozkurt, Resmiye Irmak Yüzügüldü, E. Özgür, Sait Ki̇tapli, Özgür Tanrıverdi","doi":"10.37047/jos.2023-96095","DOIUrl":"https://doi.org/10.37047/jos.2023-96095","url":null,"abstract":"ABS TRACT Lobular capillary hemangioma (LCH) or pyogenic granuloma is a rare benign lesion originating from the nasal cavity. We pre-sent a case of nasal LCH successfully palliated with sunitinib. A 65-year-old male patient was hospitalized because of swelling and hyper-emia in the periorbital region for 3 months. A month before admission, episodic epistaxis occurred. Magnetic resonance imaging showed a 35×62×63-mm solid mass filling the right half of the nasal cavity. The biopsy showed LCH, and the patient was diagnosed with metastatic renal cell carcinoma (RCC). The tumor board discussed a strategy that can primarily treat metastatic RCC and symptomatic palliation of LCH. Moreover, sunitinib treatment provided palliation of symptoms related to nasal LCH. He reported that swelling, pain, and epistaxis disappeared during the treatment.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69824695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ayşe Kötek Sedef, T. Berber, Özge Kandemir Gürsel, Necla Gürdal, Berna Akkus Yildirim
{"title":"Impact of Adjuvant Chemotherapy in Patients with Medically Inoperable Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy","authors":"Ayşe Kötek Sedef, T. Berber, Özge Kandemir Gürsel, Necla Gürdal, Berna Akkus Yildirim","doi":"10.37047/jos.2023-95681","DOIUrl":"https://doi.org/10.37047/jos.2023-95681","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69824719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
İ. Gökmen, A. Gökyer, Fahri Akgül, Erkan Özcan, A. Alkan, N. Demir, I. Çiçin
ABS TRACT Objective: Immune checkpoint inhibitor-related pneumonitis (ICI-P), as a rare, immune-related adverse event, is difficult to diagnose and treat for clinicians because of its life-threatening adverse events and nonspecific clinical and laboratory findings. Material and Methods: Patients with newly developed pulmonary infiltrates receiving ICI for cancer treatment were included in this study, and their images were re-evaluated by a radiologist. Results: In this study, 32 (88.9%) male and four (11.3%) female patients with a median age of 62 years (range: 20-70 years) were enrolled, of whom 26 patients (72.3%) were diagnosed with non-small cell lung cancer. The most frequent ICI-P-related symptom was cough (63.9%). The median time to the occurrence of ICI-P was 3.5 months (range: 0.3-20 months), and the median number of cycles was four (range: 1-25). Ten patients needed hospitalization, 13 patients were found with permanent termination of ICI therapy, and ICI-P recurred in six patients (16.7%). Other immunosuppressive treatments, such as using mycophenolate mofetil and infliximab, were required in three steroid-refractory patients. No patient died due to uncontrolled ICI-P. Conclusion: In our study, consolidation was the most common radiological finding of ICI-P, which may involve the contralateral side as well as the tumor margin, possibly mimicking lymphangitic spread. Although ICI-P diagnosis is based on the exclusion of other differential diagnoses, it can mimic many other clinical conditions. Empirical use of steroids should not be avoided if there is clinical suspicion because of the risk of mortality.
{"title":"Clinical and Radiological Features and Treatment of Pulmonary Toxicity Associated with Using Immune Checkpoint Inhibitors in Cancer Treatment: A Single-Center Experience","authors":"İ. Gökmen, A. Gökyer, Fahri Akgül, Erkan Özcan, A. Alkan, N. Demir, I. Çiçin","doi":"10.37047/jos.2023-95972","DOIUrl":"https://doi.org/10.37047/jos.2023-95972","url":null,"abstract":"ABS TRACT Objective: Immune checkpoint inhibitor-related pneumonitis (ICI-P), as a rare, immune-related adverse event, is difficult to diagnose and treat for clinicians because of its life-threatening adverse events and nonspecific clinical and laboratory findings. Material and Methods: Patients with newly developed pulmonary infiltrates receiving ICI for cancer treatment were included in this study, and their images were re-evaluated by a radiologist. Results: In this study, 32 (88.9%) male and four (11.3%) female patients with a median age of 62 years (range: 20-70 years) were enrolled, of whom 26 patients (72.3%) were diagnosed with non-small cell lung cancer. The most frequent ICI-P-related symptom was cough (63.9%). The median time to the occurrence of ICI-P was 3.5 months (range: 0.3-20 months), and the median number of cycles was four (range: 1-25). Ten patients needed hospitalization, 13 patients were found with permanent termination of ICI therapy, and ICI-P recurred in six patients (16.7%). Other immunosuppressive treatments, such as using mycophenolate mofetil and infliximab, were required in three steroid-refractory patients. No patient died due to uncontrolled ICI-P. Conclusion: In our study, consolidation was the most common radiological finding of ICI-P, which may involve the contralateral side as well as the tumor margin, possibly mimicking lymphangitic spread. Although ICI-P diagnosis is based on the exclusion of other differential diagnoses, it can mimic many other clinical conditions. Empirical use of steroids should not be avoided if there is clinical suspicion because of the risk of mortality.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69824786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ABS TRACT Objective: Metastatic pancreatic cancer is a common condition and highly lethal condition, emphasizing the urgent need for novel prognostic markers. This study investigated the effect of the gamma-glutamyl transferase/albumin ratio (GAR) and alkaline phosphatase/albumin ratio (APAR) on prognosis. Material and Methods: We conducted a retrospective examination 287 patients diagnosed with metastatic pancreatic cancer between January 2008 2019. Results: The median age was 65 years, and obstructive jaundice was present in 58 (20.2%). Median overall-surviva (OS) was significantly longer in patients without jaundice (6.0 vs. 3.0 months, p=0.005). Furthermore, median OS and progression-free survival (PFS) were extended in the low-GAR-group (6.0 vs. 4.0 months, p=0.001; 5.0 vs. 3.0 months, p<0.01, respectively). Similarly, patients in the low APAR group exhibited longer median OS and PFS (6.0 vs. 3.0 months, p<0.01; 5.0 vs. 3.0 months, p<0.01, respectively). The low neutrophil-to-lymphocyte-ratio (NLR) group demonstrated prolonged median OS and PFS (8.0 vs. 3.0 months, p<0.01; 6.0 vs. 3.0 months, p<0.01, respectively). Additionally, patients in the high prognostic-nutritional-index (PNI) group experienced extended median OS and PFS (6.0 vs. 3.0 months, p<0.01; 5.0 vs. 2.0 months, p=0.02, respectively). Furthermore, members of the low-GAR-group were significantly more prevalent in the low-NLR and low platelet-to-lymphocyte-ratio-groups (79.4% vs. 20.6%, p=0.02 and 75.9% vs. 24.1%, p=0.04, respectively). By contrast, the low-APAR-group had significantly more members than the high-PNI-group (90% vs. 10%, p<0.01). Conclusion: In metastatic pancreatic cancer, both OS and PFS significantly extend in the low-GAR, APAR, and NLR groups, while the high-PNI-group also exhibits enhanced OS and PFS. These findings must be supported by further studies .
{"title":"Gamma-Glutamyl Transferase/Albumin Ratio and Alkaline Phosphatase/Albumin Ratio as Novel Prognostic Markers for Metastatic Pancreatic Cancer","authors":"Elif YÜCE, Evren FİDAN","doi":"10.37047/jos.2022-94940","DOIUrl":"https://doi.org/10.37047/jos.2022-94940","url":null,"abstract":"ABS TRACT Objective: Metastatic pancreatic cancer is a common condition and highly lethal condition, emphasizing the urgent need for novel prognostic markers. This study investigated the effect of the gamma-glutamyl transferase/albumin ratio (GAR) and alkaline phosphatase/albumin ratio (APAR) on prognosis. Material and Methods: We conducted a retrospective examination 287 patients diagnosed with metastatic pancreatic cancer between January 2008 2019. Results: The median age was 65 years, and obstructive jaundice was present in 58 (20.2%). Median overall-surviva (OS) was significantly longer in patients without jaundice (6.0 vs. 3.0 months, p=0.005). Furthermore, median OS and progression-free survival (PFS) were extended in the low-GAR-group (6.0 vs. 4.0 months, p=0.001; 5.0 vs. 3.0 months, p<0.01, respectively). Similarly, patients in the low APAR group exhibited longer median OS and PFS (6.0 vs. 3.0 months, p<0.01; 5.0 vs. 3.0 months, p<0.01, respectively). The low neutrophil-to-lymphocyte-ratio (NLR) group demonstrated prolonged median OS and PFS (8.0 vs. 3.0 months, p<0.01; 6.0 vs. 3.0 months, p<0.01, respectively). Additionally, patients in the high prognostic-nutritional-index (PNI) group experienced extended median OS and PFS (6.0 vs. 3.0 months, p<0.01; 5.0 vs. 2.0 months, p=0.02, respectively). Furthermore, members of the low-GAR-group were significantly more prevalent in the low-NLR and low platelet-to-lymphocyte-ratio-groups (79.4% vs. 20.6%, p=0.02 and 75.9% vs. 24.1%, p=0.04, respectively). By contrast, the low-APAR-group had significantly more members than the high-PNI-group (90% vs. 10%, p<0.01). Conclusion: In metastatic pancreatic cancer, both OS and PFS significantly extend in the low-GAR, APAR, and NLR groups, while the high-PNI-group also exhibits enhanced OS and PFS. These findings must be supported by further studies .","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134887735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) has been proved in the treatment of left-sided RAS wild-type unresectable metastatic colorectal cancer. However, their effectiveness in the early stages of the disease has been questioned. Previous studies have shown that the use of these drugs in an adjuvant setting was not effective and recent evidence suggests that they are also ineffective in patients with resectable liver metastases. Neoadjuvant therapy is currently the standard of care for many types of cancer, and studies in this field are ongoing. There is limited data available on the efficacy of anti-EGFR MoAbs in the treatment of locally advanced colon cancer, and a recent study showed no benefit. This review focused on the perioperative use of anti-EGFR MoAbs in the treat-ment of resectable colon cancer and explored possible explanations for their low effectiveness.
{"title":"Efficacy of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Resectable Colon Cancer","authors":"Yakup ERGÜN","doi":"10.37047/jos.2023-95963","DOIUrl":"https://doi.org/10.37047/jos.2023-95963","url":null,"abstract":"of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) has been proved in the treatment of left-sided RAS wild-type unresectable metastatic colorectal cancer. However, their effectiveness in the early stages of the disease has been questioned. Previous studies have shown that the use of these drugs in an adjuvant setting was not effective and recent evidence suggests that they are also ineffective in patients with resectable liver metastases. Neoadjuvant therapy is currently the standard of care for many types of cancer, and studies in this field are ongoing. There is limited data available on the efficacy of anti-EGFR MoAbs in the treatment of locally advanced colon cancer, and a recent study showed no benefit. This review focused on the perioperative use of anti-EGFR MoAbs in the treat-ment of resectable colon cancer and explored possible explanations for their low effectiveness.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134887741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Karakaya, Özgen Ahmet Yıldırım, Şeyma Işik, Ş. Yücel, I. Karadag
{"title":"Lorlatinib-Related Vision Loss: Two Cases of Non-Small Cell Lung Cancer with Blindness","authors":"S. Karakaya, Özgen Ahmet Yıldırım, Şeyma Işik, Ş. Yücel, I. Karadag","doi":"10.37047/jos.2022-92714","DOIUrl":"https://doi.org/10.37047/jos.2022-92714","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69824039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Z. Urakçı, S. Ebinç, Z. Oruç, M. Kaplan, M. Küçüköner, A. Işıkdoğan
{"title":"Effectiveness of Current First-Line Treatments and Evaluation of Prognostic Factors Related to Survival in Castration-Resistant Prostate Cancer with Isolated Bone Metastasis","authors":"Z. Urakçı, S. Ebinç, Z. Oruç, M. Kaplan, M. Küçüköner, A. Işıkdoğan","doi":"10.37047/jos.2023-95447","DOIUrl":"https://doi.org/10.37047/jos.2023-95447","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69824668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Ay, M. Atçı, R. Arıkan, Ö. Dülgar, D. Tataroğlu Özyükseler, M. Gümüş
{"title":"Initial Albumin-Bilirubin Grade as a Prognostic Indicator of Pancreatic Cancer with Liver Metastasis","authors":"S. Ay, M. Atçı, R. Arıkan, Ö. Dülgar, D. Tataroğlu Özyükseler, M. Gümüş","doi":"10.37047/jos.2021-87242","DOIUrl":"https://doi.org/10.37047/jos.2021-87242","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69821631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sümeyye Teki̇n, A. Tatlı, Sema Sezgin Göksu, H. Coşkun
seen in patients with gastrointestinal system cancer; affects prognosis, quality of life, and survival. In this study, the prognostic value of the Prognostic Nutritional Index (PNI) and Geriatric Nutritional Risk Index (GNRI) based on malnutrition and systemic inflammatory response were compared to determine which index was more predictive for survival. Material and Methods: A total of 124 patients were included in the study. Statistical analysis was done with SPSS program. Kaplan-Meier analysis and Log-Rank test were used for survival analysis. Factors affecting overall survival (OS) were analyzed with univariate and multivariate Cox regression analysis. The values of the indices in predicting the cutoff point and OS were recorded by calculating area under the curve by receiver operating characteristic analysis. Results: In univariate analysis; primary tumor location at the cardioesophageal junction, increased CRP, decreased lymphocyte count, and low PNI ( ≤ 44.05) significantly decreased OS (p<0.05). Only the primary tumor location at the car-dioesophageal junction was an independent prognostic factor for mortality (hazard ratio: 2.717; 95% confidence interval: 1.292-5.711; p=0.008). Conclusion: Although PNI is not an independent risk factor for OS in patients with metastatic gastric cancer, it can be an indicator of survival. In addition, PNI was found to be a better prognostic marker in predicting OS than GNRI.
{"title":"Prognostic Nutritional Index Predicts Overall Survival Better than Geriatric Nutritional Risk Index in Patients with Metastatic Gastric Cancer","authors":"Sümeyye Teki̇n, A. Tatlı, Sema Sezgin Göksu, H. Coşkun","doi":"10.37047/jos.2023-96450","DOIUrl":"https://doi.org/10.37047/jos.2023-96450","url":null,"abstract":"seen in patients with gastrointestinal system cancer; affects prognosis, quality of life, and survival. In this study, the prognostic value of the Prognostic Nutritional Index (PNI) and Geriatric Nutritional Risk Index (GNRI) based on malnutrition and systemic inflammatory response were compared to determine which index was more predictive for survival. Material and Methods: A total of 124 patients were included in the study. Statistical analysis was done with SPSS program. Kaplan-Meier analysis and Log-Rank test were used for survival analysis. Factors affecting overall survival (OS) were analyzed with univariate and multivariate Cox regression analysis. The values of the indices in predicting the cutoff point and OS were recorded by calculating area under the curve by receiver operating characteristic analysis. Results: In univariate analysis; primary tumor location at the cardioesophageal junction, increased CRP, decreased lymphocyte count, and low PNI ( ≤ 44.05) significantly decreased OS (p<0.05). Only the primary tumor location at the car-dioesophageal junction was an independent prognostic factor for mortality (hazard ratio: 2.717; 95% confidence interval: 1.292-5.711; p=0.008). Conclusion: Although PNI is not an independent risk factor for OS in patients with metastatic gastric cancer, it can be an indicator of survival. In addition, PNI was found to be a better prognostic marker in predicting OS than GNRI.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69825488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：